Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020